检索结果-南通市图书馆

Chinese expert consensus on clinical application of molecularly targeted drugs for hepatocellular carcinoma (2022 edition)

在线全文

学校读者我要写书评

暂无评论

中华医学杂志(英文版) 2024年第21期137卷 2630页

作者： Sun Juxian Li Qiu Bai Xueli Cai Jianqiang Chen Yajin Chen Minshan Dai Chaoliu Fang Chihua Jia Weidong Li Xiangcheng Wen Tianfu Xia Jinglin ying mingang Zhang Zhiwei Zhang Xuewen Zeng Zhaochong Cheng Shuqun Department of Hepatic Surgery VI Eastern Hepatobiliary Surgery Hospital Naval Medical University Shanghai China Department of Medical Oncology Cancer Center West China Hospital Sichuan University Chengdu Sichuan China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China Department of Hepatobiliary Surgery Cancer Hospital Chinese Academy of Medical Sciences Beijing China Department of Hepatobiliopancreatic Surgery Sun Yat-Sen Memorial Hospital Sun Yat-Sen University Guangzhou Guangdong China Department of Hepatobiliary Surgery Sun Yat-sen University Cancer Center Guangzhou Guangdong China Department of Hepatobiliary and Spleenary Surgery The Affiliated Shengjing Hospital China Medical University Shenyang Liaoning China Department of Hepatobiliary Surgery Zhujiang Hospital First Military Medical University Guangzhou Guangdong China Department of General Surgery Anhui Key Laboratory of Hepatopancreatobiliary Surgery Anhui Provincial Hospital The First Affiliated Hospital of USTC University of Science and Technology of China Hefei Anhui China Hepatobiliary Center The First Affiliated Hospital of Nanjing Medical University Key Laboratory of Living Donor Liver Transplantation Nanjing Jiangsu China Department of Liver Surgery West China Hospital of Sichuan University Chengdu Sichuan China The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang China Liver Cancer Institute & Zhongshan Hospital Fudan University Shanghai China Department of Gastrointestinal Oncological Surgery Fujian Provincial Cancer Hospital Fujian Medical University Teaching Hospital Fuzhou Fujian China Department of Surgery Hepatic Surgery Center Institute of HBP Surgery Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China Department of Hepatobiliary and Pancreas Surgery The Second Hospital of Jilin University Changc

[3] Many targeted drugs have been developed for different treatment purposes and for different patient populations, and the way in which these therapies are selected to achieve a maximum benefit has been left up to individual clinicians due to the absence of authoritative guidelines.After progression is observed by imaging during treatment with first-line targeted drugs, a timely comprehensive evaluation should be performed to determine the appropriate second-line treatment (IIb, B).Many clinical studies have demonstrated that molecularly targeted drugs are effective treatments for advanced HCC, as they have good objective response rate (ORRs) and obvious survival benefits.Funding This work is supported by grants from the State Key Project of the National Natural Science Foundation of China (No. 81730097), the Clinical Science and Technology Innovation Project of Shanghai Shenkang Hospital Development Center (Joint Project of Emerging Frontier Technology) (No.

关键词：

Effect of dendritic cell-cytokine induced killer cells in patients with triple-negative breast cancer

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Effect of dendritic cell-cytokine induced killer cells in pa...

第十一届全国免疫学学术大会

作者： Xie Yunqing Liu Jian Lin Xiaowei Liu Shijia ying mingang Zheng Qiuhong Fujian Provincial Key Laboratory of Tumor Biotherapy

Purpose: Triple-negative breast cancer(TNBC) is a breast cancer type with poor prognosis due to the absence of targets for the treatment of endocrine and anti-HER-2 therapy. Furthermore, only about 20% of TNBC are sensitive to conventional chemotherapy. Therefore, this study aimed to evaluate the clinical efficacy of adjuvant dendrtic cell(DC)-cytokineinduced killer cells(CIK) immunotherapy combined with chemotherapy with/without radiotherapy in patients with postoperative ***: From December 1,2006 to February28,2011, 68 patients with postoperative TNBC were included in this retrospective study: 43 cases received chemotherapy with/without radiotherapy;25 cases received DC-CIK cells infusion combined with chemotherapy with/without ***: Survival analysis showed the 5-years disease-free survival(DFS) rate was significantly higher in the DC-CIK group compared with the non- DC-CIK group(P=0.049). Further subgroup analysis stratified according to tumor–node–metastasis(TNM) stages showed that the 5-years DFS was significantly increased in DC-CIK group with advanced TNM stages(including IIb,III,IV TNM stage) than the non- DC-CIK, and 5-year OS rate in advanced-stage subgroup was also improved although it only approved borderline statistical significance(P=0.051).Conclusions: Our results demonstrated that TNBC patients with advanced TNM stages could benefitted from adjuvant DC-CIK cells infusion combined with conventional therapy in terms of preventing disease relapse and increasing overall survival.

关键词： dendritic cells cytokine-induced killer cells adjuvant immunotherapy triple-negative breast cancer

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

腹腔镜低位直肠癌保肛手术新进展

中国肿瘤临床 2014年第14期41卷 881-884页

作者：应敏刚叶青黄峰福建省肿瘤医院胃肠肿瘤外科福州市350014

低位直肠癌在我国发病率逐年上升,严重威胁着人民的健康。外科手术是低位直肠癌最有效的治疗方法,随着对直肠解剖生理和低位直肠癌生物学特点研究的不断深入,低位直肠癌保肛手术得到越来越广泛的应用,尤其腹腔镜技术的应用已成为当前关... 详细信息

低位直肠癌在我国发病率逐年上升,严重威胁着人民的健康。外科手术是低位直肠癌最有效的治疗方法,随着对直肠解剖生理和低位直肠癌生物学特点研究的不断深入,低位直肠癌保肛手术得到越来越广泛的应用,尤其腹腔镜技术的应用已成为当前关注的热点问题之一。腹腔镜低位直肠前切除术、腹腔镜低位直肠前切除术联合经肛门括约肌间切除或经肛门直肠脱出外翻等术式是腹腔镜下低位直肠癌切除保肛手术可选的手术方法。消化道重建可选择双吻合器法、手工经肛结肠肛管吻合以及结肠J型储袋成形吻合等方式。各种术式有其特有的适应范围和优缺点,应以优先保证手术根治同时兼顾生活质量为原则合理选择术式。

关键词：低位直肠癌腹腔镜保肛手术

MicroRNA-148b suppresses hepatic cancer stem cell by targeting neuropilin-1

在线全文

学校读者我要写书评

暂无评论

MicroRNA-148b suppresses hepatic cancer stem cell by targeti...

第十四届全国肿瘤生物治疗大会

作者： Qinying Liu Yangmei Xu Shenghong Wei Wei Gao mingang ying Qiuhong Zheng Fujian Provincial Key Laboratory of Tumor Biotherapy Teaching Hospital of Fujian Medical University Fujian Provincial Tumor Hospital Department of Abdominal Surgery Teaching Hospital of Fujian Medical University Fujian Provincial Tumor Hospital Department of Abdominal Tumor Teaching Hospital of Fujian Medical University Fujian Provincial Tumor Hospital

Background: The existence of cancer stem cells is considered as a direct reason for the failure of clinic treatment in hepatocellular carcinoma. Growing evidences have demonstrated that micro RNAs play an important role in regulation of stem cell proliferation, differentiation and self-renewal, and their aberrances cause the formation of cancer stem cells and eventually result in carcinogenesis. Purpose: We recently identified micro RNA-148 b as one of the micro RNAs specifically down-regulated in side population cells of PLC/PRF/5 cell line. However, it remains elusive how micro RNA-148 b regulates cancer stem cell properties in hepatocellular carcinoma. Methods: Side population(SP) cells were analyzed by flow cytometry. micro RNA and CSC-related gene were analyzed by QRT-PCR. mi R-148 b was knocked-down or over-expressed by lentiviral transfection. Real time cellular analysis, soft agar assay, tumor invasion assay and tumorigenicity experiment were performed to analyze CSC-like properties. Dual luciferase assay was used to identify the target gene. Xenograft tumor model was used to test the tumorigenicity of mi R-148 b knocked-down or over-expressed tumor cells. Results: In this study, we observed that over-expression or knock-down of mi R-148 b through lentiviral transfection could affect the proportion of side population cells as well as cancer stem cell-related gene expression in hepatocellular carcinoma cell lines. In addition, mi R-148 b blocking could stimulate cell proliferation, enhance chemosensitivity,as well as increase cell metastasis and angiogenesis in vitro. More importantly, mi R-148 b could significantly suppress tumorigenicity in vivo. Further studies revealed that Neuropilin-1, a transmembrane coreceptor involved in tumor initiation, metastasis and angiogenesis, might be the direct target of micro RNA-148 b. Conclusion:Taking together, our findings define that mi R-148 b might play a critical role in maintenance of side population cells with can

关键词： microRNA-148b side population cell Neuropilin-1 hepatocellular carcinoma cancer stem cell

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

Ⅲ期乳腺癌新辅助化疗的近期疗效观察

中国临床医学 2008年第5期15卷 717-718页

作者：黄峰周东应敏刚福建省肿瘤医院腹部外科福建福州350014

目的:探讨不同周期的新辅助化疗对Ⅲ期乳腺癌近期疗效、毒性反应及保乳率的影响。方法:243例Ⅲ期乳腺癌患者接受5-氟尿嘧啶+环磷酰胺+表阿霉素(CEF方案)进行新辅助化疗(NAC)。其中141例完成2个周期化疗,102例完成4个周期化疗,对两组的... 详细信息

目的:探讨不同周期的新辅助化疗对Ⅲ期乳腺癌近期疗效、毒性反应及保乳率的影响。方法:243例Ⅲ期乳腺癌患者接受5-氟尿嘧啶+环磷酰胺+表阿霉素(CEF方案)进行新辅助化疗(NAC)。其中141例完成2个周期化疗,102例完成4个周期化疗,对两组的近期疗效(包括肿瘤大小与化疗疗效)、毒性反应及保乳率进行比较分析。结果:NAC2周期组的总有效率为61.0%(86/141),其中临床完全缓解(CR)27例,部分缓解(PR)59例,无变化(NC)55例。保乳率为27.66%(34/141)。4周期组的总有效率为66.7%(68/102),CR25例,PR43例,NC34例,保乳率为34.31%(37/102)。两组均无进展病例。两组间化疗毒性反应比较,4周期组重于2周期组。结论:对Ⅲ期乳腺癌用CEF方案进行NAC,在肿瘤大小、化疗疗效等近期疗效上,2周期组与4周期组无显著差异;不良反性反应,4周期组重于2周期组;保乳率,4周期组优于2周期组。

关键词：乳腺肿瘤药物疗法 5-氟脲嘧啶环磷酰胺表阿霉素

Inhibitor of DNA binding 1(Id1) knockdown inhibits stemness and reverses EMT of colorectal cancer cells

在线全文

学校读者我要写书评

暂无评论

Inhibitor of DNA binding 1(Id1) knockdown inhibits stemness ...

第十四届全国肿瘤生物治疗大会

作者： Xiaolan Lai Jinrong Liao Lei Cao mingang ying Wansong Lin Chuanzhong Huang Jieyu Li Shuping Chen Chao Li Chunkang Yang Qiang Chen Yunbin Ye Graduate School of Education Fujian Medical University Department of Abdominal Surgery Fujian Provincial Cancer Hospital Department of Immuno-Oncology Laboratory Fujian Provincial Cancer Hospital Fujian Key Laboratory of Translational Cancer Medicine Department of Pathology Fujian Provincial Cancer Hospital Fuzhou Department of Medical Oncology Union Hospital of Fujian Medical University

Background: Inhibitor of DNA binding 1(Id1) is essential for the maintenance of self-renewal of neural and embryonic stem cells;however, its roles in human colorectal stem-like cells(CSCs) and epithelialmesenchymal transition(EMT) are still elusive. Materials and Methods: The messenger RNA(mR NA) and protein levels of Id1 and CD133 were detected by reverse transcription quantity PCR, immunohistochemistry analysis in normal mucosa and primary colorectal cancer(CRC) specimens. Id1 was stably knockdown(KD) in human colon cancer cell lines by RNA interference method. Spheres forming assay and tumorigenic assay were performed to evaluate self-renewal capacity in vitro and tumor initiate in vivo, respectively. CSC and EMT relative makers and TCF/LEF promoter activity were assessed after Id1 KD in HCT116 cells. Results: Id1 protein expression was significantly related with CRC differentiation status, however, CD133 expression was positively related with T categories in 75 CRC patients. Spearman correlation revealed that Id1 expression was significantly and positively correlated with CD133 expression in both mR NA(r=0.401, P=0.031) and protein levels(r=0.309, P=0.005). Id1 KD of HCT116 caused decreased sphere-formation capacity compared to the controls. Likewise,CD133 and several other stem cell makers expression in the Id1 KD cells were remarkably reduced compared to the control cells. The Id1 KD cells also demonstrated up-regulated E-cadherin and down-regulated snail and twist expression, which are the typical phenotype of EMT. And also, the down-regulation of nucleus and cytoplasm β-catenin and the TCF/LEF promoter activity was detected in Id1 KD cells compared that in controls. In vivo test confirmed that down-regulation of Id1 led to decrease tumor-initiating ability and suppress tumor growth in nude mice. Conclusion: Our findings indicate that down-regulation of Id1 can suppress the self-renewal and reverse EMT features of CRC, possibly through Wnt pathway. Id1 could

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

胃黏膜相关淋巴样组织淋巴瘤42例临床分析

中国肿瘤临床 2011年第13期38卷 797-800页

作者：卓长华应敏刚梁寒臧卫东陈路川福建医科大学教学医院福建省肿瘤医院腹外科福州市350014 天津医科大学附属肿瘤医院胃部肿瘤科天津市肿瘤防治重点实验室

目的:探讨胃黏膜相关淋巴样组织淋巴瘤的临床表现、病理特征和治疗方法。方法:回顾性分析1990年7月至2008年5月间42例胃MALT淋巴瘤的病理特征和临床分期等资料,并按治疗方式不同划分为单纯根除Hp组(7例)、单纯手术组(9例)、手术+根除Hp... 详细信息

目的:探讨胃黏膜相关淋巴样组织淋巴瘤的临床表现、病理特征和治疗方法。方法:回顾性分析1990年7月至2008年5月间42例胃MALT淋巴瘤的病理特征和临床分期等资料,并按治疗方式不同划分为单纯根除Hp组(7例)、单纯手术组(9例)、手术+根除Hp组(20例)、手术+放、化疗组(6例),对各治疗组随访结果使用Kaplan-Meier方法进行生存率分析,LogRank检验评估各组间的统计学差异。结果:全组患者均接受胃镜检查,确诊率26.2%(11/42),HP染色阳性率70.6%(24/34)。免疫表型分析证实全部为B细胞性淋巴瘤。全组Cotswolds改良Ann Arbor分期:Ⅰ E2期17例,ⅡE1期16例,ⅡE2期6例,ⅢE期2例,Ⅳ期1例。各组5年生存率分别为100%、83.7%、82.4%及43.0%(P=0.027)。结论:胃MALT淋巴瘤的临床表现和辅助检查均无明显特异性,故初治时接受手术治疗的患者较多病理确诊者可首选根除Hp治疗,疗效与手术无异;晚期患者可在术后选择放、化疗等综合治疗,但远期生存率相对较差。

关键词：黏膜相关淋巴样组织胃原发性淋巴瘤幽门螺杆菌免疫表型分析生存分析

在线全文

学校读者我要写书评

暂无评论

原发性肝癌术后腹腔种植转移危险因素分析

中国临床医学 2011年第6期18卷 800-802页

作者：黄峰周东应敏刚福建省肿瘤医院腹部外科福建福州350014

目的:探讨影响原发性肝癌术后腹腔种植转移的危险因素。方法:回顾分析2001年1月—2005年12月35例原发性肝癌术后腹腔种植转移病例及287例同期术后无腹腔种植转移病例的临床资料,并进行统计学分析。结果:单因素分析结果显示肿瘤大小、癌... 详细信息

目的:探讨影响原发性肝癌术后腹腔种植转移的危险因素。方法:回顾分析2001年1月—2005年12月35例原发性肝癌术后腹腔种植转移病例及287例同期术后无腹腔种植转移病例的临床资料,并进行统计学分析。结果:单因素分析结果显示肿瘤大小、癌灶是否破裂及癌灶是否侵犯周围脏器与原发性肝癌术后腹腔种植转移显著相关。多因素分析结果显示肿瘤大小、癌灶是否破裂是影响原发性肝癌术后腹腔种植转移的独立危险因素。结论:引起原发性肝癌术后腹腔种植转移的主要危险因素是较大肝癌、肝癌破裂及癌灶侵犯周围脏器等。术中注意癌灶的隔离、癌旁受侵组织的分离、无瘤操作原则及腹腔反复冲洗等可减小腹腔种植转移概率,从而改善预后。

关键词：肝癌腹腔种植转移危险因素

在线全文

学校读者我要写书评

暂无评论

热休克蛋白70多肽复合物与肿瘤免疫

福建医科大学学报 2006年第3期40卷 308-310,F0003页

作者：胡廷辉应敏刚福建医科大学教学医院福建省肿瘤医院腹部外科福州350014

热休克蛋白(HSP)与肿瘤免疫治疗的关系是近年来肿瘤免疫治疗的热点之一。许多研究结果均证实,从肿瘤组织中提取HSP能诱导机体产生对该肿瘤细胞的免疫应答,达到治疗肿瘤的目的。HSP分子实际上是分子量大小不同的一组蛋白,根据HSP的同源... 详细信息

热休克蛋白(HSP)与肿瘤免疫治疗的关系是近年来肿瘤免疫治疗的热点之一。许多研究结果均证实,从肿瘤组织中提取HSP能诱导机体产生对该肿瘤细胞的免疫应答,达到治疗肿瘤的目的。HSP分子实际上是分子量大小不同的一组蛋白,根据HSP的同源程度及分子量的大小差异,可分为HSP110家族、HSP90家族、HSP70家族、HSP60家族及小HSP家族,其中HSP70在肿瘤免疫中发挥重要的作用。[第一段]

关键词：热休克蛋白70 癌症疫苗免疫疗法